RARG and prostate carcinoma: Similarly, treatment of the prostate cancer cell lines DU-145, LNCaP, and PC3 with the RARγ agonist AGN205327, or a low level of ATRA to activate just RARγ, stimulated cell growth and colony formation by the cancer stem cell-like cells.